Júlia Calvo Jimenez

Dr. Júlia Calvo Jimenez

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
AFAlberto Foncillas
Alberto Foncillas
JAJuan Ambrosioni
Juan Ambrosioni
ASAbiu Sempere
Abiu Sempere
LBLeire Berrocal
Leire Berrocal
JJJúlia Calvo Jimenez
Júlia Calvo Jimenez
MLMontserrat Laguno
Montserrat Laguno
Background: Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) therapy for HIV, lacks activity against hepatitis B virus (HBV). We evaluate HBV serological profiles and risk of HBV reactivation (HBVr) or incident infection (HBVi) in people with HIV (PWH) switching to LA-CAB/RPV. Methods: Prospective cohort study of PWH initiating LA-CAB/RPV at Hospital Clínic Barcelona between February/2023 and February/2025. HBV serology, vaccination status, and liver function tests (LFTs) were assessed at baseline. Follow-up LFTs were performed routinely (weeks 12, 28, and every 6 months), and HBV serology/DNA assessed if abnormal LFTs, acute hepatitis or clinical suspicion of reactivation. HBVr was defined as conversion from HBsAg negative to positive or detectable HBV DNA in anti-HBc-positive/HBsAg-negative individuals, or as HBV DNA ≥1 log increase or ≥100 IU/mL in chronic HBV (HBsAg-positive) participants. HBVi was defined as HBsAg seroconversion in HBV unexposed individuals. Results: Among 741 participants-92% cis-gender male, median age 43 (IQR 35–52)-454 (61%) had vaccine-induced immunity and 25% had prior HBV exposure (anti-HBc-positive), with 3% showing isolated anti-HBc. Median follow-up was 54 weeks (IQR 28–77). No HBVr or HBVi were observed in people without chronic hepatitis at baseline. Four individuals (0.5%) with unnoticed chronic HBV infection (HBsAg-positive) started LA-CAB/RPV; two developed clinical HBVr and two remained stable after regimen switch, all four switched back to tenofovir-containing therapy. Transaminase elevations during follow-up occurred in 17% of the cohort, regardless of HBV serostatus. Conclusions: LA-CAB/RPV appears safe in individuals with prior HBV exposure, including isolated anti-HBc. Comprehensive HBV screening, vaccination, and liver monitoring are essential.

13 December 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
PMPere Medina Martí
Pere Medina Martí
ELElisa De Lazzari
Elisa De Lazzari
MEMateu Espasa
Mateu Espasa
LMLorena de la Mora
Lorena de la Mora
MMMaria Martinez-Rebollar
Maria Martinez-Rebollar
BTBerta Torres
Berta Torres
Introduction: The incidence of pneumococcal disease (PD) in people living with HIV (PLWH) is higher than in the general population; therefore, this study aimed to analyze its incidence, clinical characteristics and vaccination coverage in PLWH. Methods: We conducted a retrospective, single-center study between 2015 and 2024 in Hospital Clínic, Barcelona, involving HIV patients who presented with PD during the study period (any patient with a microbiologically confirmed result). A descriptive analysis of cases was carried out and compared with patients who did not present PD during the study period. Results: A total of 177 episodes of PD were identified in 148 individuals, with a cumulative incidence of 1.7% (95% CI: 1.4–2.0). The median age at PD diagnosis was 45.9 (36–53) years; 64% of patients were Spanish-born; 50% of patients were men who have sex with men (MSM); the HIV transmission mode was intravenous drug use in 28% of cases; the median CD4 nadir was 181 (58–324) cells/mm3; the median CD4 prior to PD was 429 (240–663) cells/mm3; and the median peak HIV viral load (VL) was 176,839 (20,900–502,000) copies/mL. Intravenous drug use (OR 3.43; 95% CI 2.19–5.36; p < 0.001), peak HIV VL (OR 1.11; 95% CI 1.02–1.21; p = 0.011), and CD4 nadir (OR 0.92; 95% CI 0.87–0.98; p = 0.005) were independently associated with PD, and fifty-one percent of patients had not received any vaccination prior to their PD episode. Conclusion: PD incidence was high in our study and associated with poor immunological status. Research on new strategies to improve vaccination coverage and immunogenicity in PLWH is needed.

19 August 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
ICIván Chivite
Iván Chivite
MMM J Merino-Peñas
M J Merino-Peñas
AGAna González-Cordón
Ana González-Cordón
MMMaria Martinez-Rebollar
Maria Martinez-Rebollar
BTBerta Torres
Berta Torres
MLMontserrat Laguno
Montserrat Laguno
Background: Increasing heterogeneity among people with HIV requires evaluation of new follow-up strategies tailored to clinical/social complexity. Methods: Prospective, single-center, randomized, noninferiority trial comparing semi-annual standard of care (SoC) with annual follow-upover 24 months in virologically suppressed people with HIV with low-complexity profile according to the GeSIDA HIV Patient Stratification System. The primary endpoint was noninferiority (prespecified lower margin: −4%) in virological control (viral load <50 copies/mL; FDA snapshot). Secondary outcomes included adherence, quality of life, satisfaction, and healthcare costs. Results: Of 394 eligible candidates, 71 declined participation (48% preferred SoC) and 321 were randomized (162 SoC, 159 Annual). Participants were predominantly male (89%), men who have sex with men (78%), Spanish (63%), with a median age of 45 years and 13 years of HIV follow-up, without baseline differences between groups. Overall, 283 (88%) completed the study; 25 switched to long-acting therapy and 10 were lost or transferred. Virological control was similar in SoC and annual arms: 86.42% vs 86.79% (intention to treat) and 98.29% vs 97.87% (per protocol), although noninferiority was not statistically demonstrated. The proportion of highly satisfied participants increased significantly from baseline to 24 months in the annual arm (P = .001). Reductions in HIV-related direct costs (−25.3%; P < .001) were greater in the Annual group. Conclusions: Among people with HIV and low complexity, annual follow-up achieved virological outcomes clinically comparable to semi-annual care, despite not meeting the formal noninferiority threshold. Annual follow-up was associated with a significant increment in patient satisfaction and lower HIV-related direct costs.

11 June 2026 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
AGAna González-Cordón
Ana González-Cordón
JJJúlia Calvo Jimenez
Júlia Calvo Jimenez
LBLeire Berrocal
Leire Berrocal
MLMaite León-Fabo
Maite León-Fabo
MMMaria Martinez-Rebollar
Maria Martinez-Rebollar
BTBerta Torres
Berta Torres
Introduction Long-acting intramuscular cabotegravir plus rilpivirine (LA-CAB/RPV) administered every 2 months (Q2M) has been available in Spain since January 2023 as a switch strategy for HIV treatment. We evaluated characteristics, effectiveness, tolerability, and acceptance, including patient-reported outcomes, stratified by sex in people with HIV switching to LA-CAB/RPV. Methods Observational, prospective, cohort study in Hospital Clínic of Barcelona, Spain. Participant characteristics according to sex at birth and treatment effectiveness [HIV-RNA < 50 copies/mL by on treatment (OT), modified intention-to-treat (mITT), and intention to-treat (ITT) analyses] were evaluated. Self-administered electronic questionnaires were collected. Results From February 2023 to February 2025, 57/741 (8%) women and 684/741 (92%) men started LA-CAB/RPV, compared to 816/5901 (14%) women that continued with other antiretroviral therapy (ART) (p < 0.001) in our cohort. Women were older, had longer time since HIV diagnosis and on ART, lower nadir CD4, and were more frequently Spanish-born than men. Effectiveness by OT, mITT, and ITT in the 461 participants (29 women and 432 men) who reached week 52 of follow-up was 96%, 83%, and 83% and 99%, 92%, and 89%, respectively, without significant differences. There were 8 (1.7%) confirmed virological failures and 40 (9%) discontinuations with no significant differences by sex. Acceptance, tolerability of injections, and HIV medication burden globally improved during follow-up. Women reported more medication burden and disclosure worries than men. Conclusions Compared to our general cohort, proportionally fewer women than men switched to LA-CAB/RPV. Effectiveness, adherence, tolerability, and acceptance were high without significant differences by sex. In this study, women expressed more frequent disclosure issues and showed significantly different baseline characteristics compared to men, highlighting the importance of sex-disaggregated data analysis. These results should be confirmed in larger studies.

9 August 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
GȘGiulia Teodora Cosmulescu Șpaiuc
Giulia Teodora Cosmulescu Șpaiuc
JMJoan Gil Minana
Joan Gil Minana
LMLorena de la Mora
Lorena de la Mora
CPCristina Pitart
Cristina Pitart
LBLeire Berrocal
Leire Berrocal
MMMaria Martinez-Rebollar
Maria Martinez-Rebollar
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections are increasingly reported among gay, bisexual, and other men who have sex with men (GBMSM) engaging in chemsex, yet data remain limited. This ambispective cohort study conducted at Hospital Clínic of Barcelona (2018–2024) aimed to characterize CA-MRSA infections among GBMSM living with HIV. Methods: Epidemiological, behavioral, and clinical data were collected from medical records and standardized questionnaires. MRSA isolates from clinically indicated samples were identified by mass spectrometry and underwent antimicrobial susceptibility testing. Results: Among 446 participants, 62 (14%) were diagnosed with CA-MRSA, accounting for 109 infection episodes over a median follow-up of 3.21 years (IQR 1.39–5.05). All episodes involved skin and soft-tissue infections; 17% required hospitalization, 35% surgery, and 51% received non-active empirical antibiotics. Recurrent infections occurred in 32% of participants, and detectable HIV viral load was present in 28% of episodes. High levels of polydrug use were reported. Resistance to clindamycin (33%), cotrimoxazole (23%), and mupirocin (96%) was observed. Decolonization was attempted in 65% of participants. Conclusions: CA-MRSA infections were frequent, with substantial recurrence and antimicrobial resistance. These findings highlight challenges for infection control and antimicrobial stewardship and support further evaluation of preventive and decolonization strategies in this population.

1 September 2026 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
ASAbiu Sempere
Abiu Sempere
LMLorena de la Mora
Lorena de la Mora
AIAlexy Inciarte
Alexy Inciarte
LBLeire Berrocal
Leire Berrocal
AGAna González-Cordón
Ana González-Cordón
JBJosé Luis Blanco
José Luis Blanco
Objectives: The objective of this study is to evaluate the efficacy, resistance profile, pharmacokinetics (PK) and safety of switching from etravirine to doravirine in virologically suppressed, treatment-experienced individuals with prior non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations (NNRTI-RAMs). Methods: DorSwitch is a prospective pilot study including 13 adults with sustained virological suppression and documented historical NNRTI-RAMs. Etravirine was replaced by doravirine while maintaining the remaining antiretroviral backbone. Drug-specific resistance penalty scores were generated using the Stanford HIV Drug Resistance Database (HIVdb) algorithm. PK analyses were performed in participants receiving darunavir/cobicistat plus doravirine. Virological, immunological, metabolic and safety outcomes were assessed over 48 weeks. Results: Twelve participants completed 48 weeks of follow-up; one discontinued at Week 4 for personal reasons while virologically suppressed. All participants evaluable at Weeks 24 and 48 maintained HIV-1 RNA < 50 copies/mL, and no virological failures occurred. The median number of NNRTI-RAMs per individual was 2 (IQR 1–3). Doravirine showed lower or equal Stanford HIVdb penalty score (HIVdb-PS) than etravirine in 11/13 participants. In two cases, higher doravirine PS were driven by Y318F and G190E mutations detected in peripheral blood mononuclear cell HIV-1 DNA; both individuals remained virologically suppressed through Week 48. In seven participants receiving darunavir/cobicistat plus doravirine, trough concentrations (Cmin) were consistent with expected exposure concentrations. Total cholesterol and LDL cholesterol decreased significantly over follow-up, while body weight showed a modest, non-significant reduction. No doravirine-related serious adverse events were observed. Conclusions: In this small, highly selected pilot cohort, switching from etravirine to doravirine as part of an otherwise suppressive regimen was associated with maintenance of virological suppression through Week 48 and a more favourable predicted NNRTI resistance profile in most participants. The favourable resistance profile, safety, metabolic effects and PK findings consistent with expected exposure—particularly in combination with darunavir/cobicistat— support further evaluation of doravirine as a switch option in carefully selected individuals with prior NNRTI failure.